IT1280014B1 - Farmaci attivi contro l'agente eziologico della sindrome da astenia cronica - Google Patents
Farmaci attivi contro l'agente eziologico della sindrome da astenia cronicaInfo
- Publication number
- IT1280014B1 IT1280014B1 IT93TO000179A ITTO930179A IT1280014B1 IT 1280014 B1 IT1280014 B1 IT 1280014B1 IT 93TO000179 A IT93TO000179 A IT 93TO000179A IT TO930179 A ITTO930179 A IT TO930179A IT 1280014 B1 IT1280014 B1 IT 1280014B1
- Authority
- IT
- Italy
- Prior art keywords
- blood
- caparsolate
- days
- etiological agent
- increase
- Prior art date
Links
- 206010003549 asthenia Diseases 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 230000001684 chronic effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 208000011580 syndromic disease Diseases 0.000 title abstract 2
- 239000008280 blood Substances 0.000 abstract 4
- 210000004369 blood Anatomy 0.000 abstract 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 3
- AXRWJSAOLNNBNI-UHFFFAOYSA-L disodium;2-[(4-carbamoylphenyl)-(carboxylatomethylsulfanyl)arsanyl]sulfanylacetate Chemical compound [Na+].[Na+].NC(=O)C1=CC=C([As](SCC([O-])=O)SCC([O-])=O)C=C1 AXRWJSAOLNNBNI-UHFFFAOYSA-L 0.000 abstract 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract 2
- 206010011985 Decubitus ulcer Diseases 0.000 abstract 1
- 102000006395 Globulins Human genes 0.000 abstract 1
- 108010044091 Globulins Proteins 0.000 abstract 1
- 206010020843 Hyperthermia Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 206010027540 Microcytosis Diseases 0.000 abstract 1
- 241001430197 Mollicutes Species 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 241001494479 Pecora Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 238000004500 asepsis Methods 0.000 abstract 1
- 229940109239 creatinine Drugs 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 abstract 1
- 238000005534 hematocrit Methods 0.000 abstract 1
- 230000036031 hyperthermia Effects 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000013465 muscle pain Diseases 0.000 abstract 1
- 238000010899 nucleation Methods 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
- 208000016261 weight loss Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
I farmaci CAPARSOLATE e FILARAMIDE, se somministrati per via endovenosa, nella quantità di 0,1 ml/Kg di peso del soggetto trattato pro die per due giorni, portano alla guarigione clinica dalla malattia (Sindrome da astenia cronica) individuabile dai seguenti sintomi : anoressia, astenia, stanchezza, ipertermia, dimagrimento, dolori muscolari, tendenza al decubito, aumento dei livelli sierici di CPK e creatinina, microcitosi, riduzione dell'ematocrito, aumento delle Alfa2 globuline, diminuzione del ferro ematico.I principi attivi sono: SODIO CAPARSOLATO e TIACETARSAMIDE SODICA. La fase ematica ematica dell'agente eziologico si osserva su strisci di sangue fissati in metanolo e colorati con il metodo May-Grunwal-Giemsa La coltivazione del germe si ottiene dal sangue prelevato in perfetta asepsi insemenzando delle piastre Columbia +5% di sangue di montone, messe ad incubare per due giorni. Appaiono piccole colonie grigio-perla simili a quelle dei micoplasmi con un punto centrale rilevato.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT93TO000179A IT1280014B1 (it) | 1993-03-17 | 1993-03-17 | Farmaci attivi contro l'agente eziologico della sindrome da astenia cronica |
| AU51601/93A AU5160193A (en) | 1993-03-17 | 1993-09-08 | Arsenic medicaments for the treatment of the chronic asthenia syndrome |
| PCT/IT1993/000093 WO1994021249A1 (en) | 1993-03-17 | 1993-09-08 | Arsenic medicaments for the treatment of the chronic asthenia syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT93TO000179A IT1280014B1 (it) | 1993-03-17 | 1993-03-17 | Farmaci attivi contro l'agente eziologico della sindrome da astenia cronica |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ITTO930179A0 ITTO930179A0 (it) | 1993-03-17 |
| ITTO930179A1 ITTO930179A1 (it) | 1994-09-18 |
| IT1280014B1 true IT1280014B1 (it) | 1997-12-23 |
Family
ID=11411264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT93TO000179A IT1280014B1 (it) | 1993-03-17 | 1993-03-17 | Farmaci attivi contro l'agente eziologico della sindrome da astenia cronica |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU5160193A (it) |
| IT (1) | IT1280014B1 (it) |
| WO (1) | WO1994021249A1 (it) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1295067B1 (it) * | 1997-09-25 | 1999-04-27 | Walter Tarello | Uso di arsenico per preparare un medicamento per il trattamento della sindrome premestruale |
| FR2838965B1 (fr) | 2002-04-26 | 2004-06-25 | Centre Nat Rech Scient | Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme |
| US8394422B2 (en) | 2002-04-26 | 2013-03-12 | Centre National De La Recherche Scientifique (Cnrs) | Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans |
-
1993
- 1993-03-17 IT IT93TO000179A patent/IT1280014B1/it active IP Right Grant
- 1993-09-08 WO PCT/IT1993/000093 patent/WO1994021249A1/en active Application Filing
- 1993-09-08 AU AU51601/93A patent/AU5160193A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ITTO930179A0 (it) | 1993-03-17 |
| AU5160193A (en) | 1994-10-11 |
| WO1994021249A1 (en) | 1994-09-29 |
| ITTO930179A1 (it) | 1994-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ahmad et al. | Platelet receptor-mediated factor X activation by factor IXa. High-affinity factor IXa receptors induced by factor VIII are deficient on platelets in Scott syndrome. | |
| HUT47217A (en) | Process for producing pharmaceutical compositions containing indol derivatives as active components | |
| BR9814018A (pt) | Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer | |
| NO894995D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive anionebytter-polymerer. | |
| DE3170245D1 (en) | Indane derivatives, methods of their preparation and compositions containing them | |
| BR0116251A (pt) | composição de lágrimas artificiais contendo uma combinação de três demulcentes | |
| JPS6322021A (ja) | 眼圧制御剤 | |
| MD1688G2 (ro) | Benzotiofen, benzofuran şi indoltiazepinone, oxazepinone şi diazepinone, compoziţie farmaceutică, metodă de inhibare a aderării leucocitelor la celulele endoteliale pentru tratamentul proceselor inflamatorii şi metodă de tratament al mamiferelor infectate cu HIV infecţie . | |
| GR1002847B (el) | Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως | |
| DK324185A (da) | 2-substituerede 1,3-propylidendiphosphonatderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf | |
| Breckenridge | Interindividual differences in the response to oral anticoagulants | |
| IT1280014B1 (it) | Farmaci attivi contro l'agente eziologico della sindrome da astenia cronica | |
| TNSN90021A1 (fr) | Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales | |
| IT1190987B (it) | Tioesteri dell'acido acetilsalicilico,procedimento per la loro preparazione e composizioni farmaceutiche che li conttengono | |
| Tosone et al. | Hemodynamic responses to nifedipine in dogs anesthetized with halothane | |
| IL88513A0 (en) | D1-5-((2-benzyl-3',4-dihydro-2h-benzopyran-6-yl)methyl)thiazolidine-2',4-dione as an anti-atherosclerosis agent | |
| NO305655B1 (no) | Antiarytmiske og kardiobeskyttende substituerte indenoylguanidiner, deres anvendelse for fremstilling av legemidler, samt legemiddel inneholdende disse | |
| Tseng et al. | The effect of a single episode of chlorhexidine irrigation on the gingival response to scaling and root planing. | |
| KR900018013A (ko) | 시아노아세트아미드 유도체, 그의 제조방법 및 그를 유효 성분으로서 함유하는 식물 병해 방제제 | |
| CLATANOFF et al. | Further observations on use of warfarin sodium in anticoagulant therapy | |
| Prehm et al. | Antibodies against proteins of streptococcal hyaluronate synthase bind to human fibroblasts and are present in patients with rheumatic fever. | |
| Wadenvik et al. | Effect of Iloprost (ZK 36 374), a novel prostacyclin analogue, on ADP-induced platelet aggregation | |
| NO166366C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive cycloalkan (1,2-c:4,3-c')dipyrazoler. | |
| Fitzgerald et al. | Inhibition of the activity of Pseudomonas toxin by methylamine | |
| DK14985D0 (da) | Selektive biologisk aktive 7-oxo-prostacyclinderivater og fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 0001 | Granted |